Commentary on Treatment of HCV infection in chronic kidney disease

Nefrologia 2011;31(5):607


Dear Editor:

I read with interest the published article by Aoufi Rabih in your journal recently. The prevalence of Hepatitis C virus (HCV) infection in hemodialysis (HD) patients varies markedly from country to country. The main risk factors for HCV infection in this special group are blood transfusions, length of dialysis time and nosocomial routes of transmission including the use of contaminated equipment and patient-to-patient exposure. Control of HCV in hemodialysis setting is possible. Integration of surveillance system for early detection, training the staffs in hemodialysis patient management, putting HCV-infected patients on the top list for renal transplantation, and using more the erythropoie tin instead blood transfusion. The prevalence of HCV infection may be underestimated according to an antibody assay alone. First of all, I would like to present a dilemma regarding liver biopsy in hemodialysis patients with HCV infection. Liver biopsy in hemodialysis patients is with higher risk of bleeding and other complication and it should be done by Trans-jugular or in very specialized center. In treatment of HCV infection in hemodialysis patients, we are not sure regarding superiority of pegylated interferon (IFN) on conventional IFN, and in a meta-analysis The pooled sustained virologic response (SVR) for standard and pegylated IFN monotherapy in random effects model was 39.1% (95% confidence interval [CI], 32.1 to 46.1) and 39.3% (95% CI, 26.5 to 52.1), respectively. The difference was not significant, but it is important to treat the patients before 40 years old and as soon as possible. Individuals on dialysis with chronic hepatitis C who were treated with interferon or pegylated interferon plus ribavirin can have higher SVR rate than dialysis patients treated with interferon or pegylated interferon alone. Administration of ribavirin with close monitoring of CBC and serum ribavirin concentration can be safe.


S.M. Alavian
Director of Baqiyatallah Research Center for Gastroenterology and Liver Disease. Tehran (Iran).

Correspondence: S.M. Alavian
Director of Baqiyatallah Research Center for Gastroenterology and Liver Disease.
14155/3651. Tehran. Iran.
alavian@thc.ir

Respuesta al comentario sobre el Manejo de la infección por el virus de la hepatitis C en la enfermedad renal crónica

Nefrologia 2011;31(5):607-8

Sr. Director:

Las diferencias en las políticas sanitarias y los protocolos de cada unidad de hemodiálisis hacen que la prevalencia de la infección crónica por el virus de la hepatitis C (VHC) sea altamente variable en la población en hemodiálisis.